protein microarray slides 9374 human proteins protoarray Search Results


htb  (ATCC)
99
ATCC htb
Htb, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/htb/product/ATCC
Average 99 stars, based on 1 article reviews
htb - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
gene exp gapdh mm99999915 g1  (Thermo Fisher)
99
Thermo Fisher gene exp gapdh mm99999915 g1
Gene Exp Gapdh Mm99999915 G1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp gapdh mm99999915 g1/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
gene exp gapdh mm99999915 g1 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
integrin a5 subunit  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc integrin a5 subunit
Figure 4. Identification of Tinagl1-Interacting Proteins (A–C) LM2 cells expressing the C-terminal HA-tagged Tinagl1 (Tinagl1-HA) were lysed and immunoprecipitated (IP) with immunoglobulin G (IgG) (control) or anti- HA antibody. The IP samples were subjected to silver staining and WB (A) before mass spectrometry analysis. Tinagl1-interacting partners were clustered with KEGG pathway analysis, and the three top pathways are shown in (B). The members of the top three pathways have overlaps. The EGFR and <t>integrin</t> b1 subunits are the core members of each pathways (C). (D and E) LM2 cells stably expressing Tinagl1-HA were lysed and IP with IgG or anti-HA antibodies. The IP samples were subjected to WB analysis with the indicated antibodies to detect the interaction with EGFR and the integrin b1 subunit (D), and with integrins av, or <t>a5</t> subunits (E). See also Figure S4.
Integrin A5 Subunit, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/integrin a5 subunit/product/Cell Signaling Technology Inc
Average 95 stars, based on 1 article reviews
integrin a5 subunit - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
human lncrna microarray v2.0  (Arraystar inc)
90
Arraystar inc human lncrna microarray v2.0
Figure 4. Identification of Tinagl1-Interacting Proteins (A–C) LM2 cells expressing the C-terminal HA-tagged Tinagl1 (Tinagl1-HA) were lysed and immunoprecipitated (IP) with immunoglobulin G (IgG) (control) or anti- HA antibody. The IP samples were subjected to silver staining and WB (A) before mass spectrometry analysis. Tinagl1-interacting partners were clustered with KEGG pathway analysis, and the three top pathways are shown in (B). The members of the top three pathways have overlaps. The EGFR and <t>integrin</t> b1 subunits are the core members of each pathways (C). (D and E) LM2 cells stably expressing Tinagl1-HA were lysed and IP with IgG or anti-HA antibodies. The IP samples were subjected to WB analysis with the indicated antibodies to detect the interaction with EGFR and the integrin b1 subunit (D), and with integrins av, or <t>a5</t> subunits (E). See also Figure S4.
Human Lncrna Microarray V2.0, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human lncrna microarray v2.0/product/Arraystar inc
Average 90 stars, based on 1 article reviews
human lncrna microarray v2.0 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
p38 mapk inhibitor  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc p38 mapk inhibitor
Figure 4. Identification of Tinagl1-Interacting Proteins (A–C) LM2 cells expressing the C-terminal HA-tagged Tinagl1 (Tinagl1-HA) were lysed and immunoprecipitated (IP) with immunoglobulin G (IgG) (control) or anti- HA antibody. The IP samples were subjected to silver staining and WB (A) before mass spectrometry analysis. Tinagl1-interacting partners were clustered with KEGG pathway analysis, and the three top pathways are shown in (B). The members of the top three pathways have overlaps. The EGFR and <t>integrin</t> b1 subunits are the core members of each pathways (C). (D and E) LM2 cells stably expressing Tinagl1-HA were lysed and IP with IgG or anti-HA antibodies. The IP samples were subjected to WB analysis with the indicated antibodies to detect the interaction with EGFR and the integrin b1 subunit (D), and with integrins av, or <t>a5</t> subunits (E). See also Figure S4.
P38 Mapk Inhibitor, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p38 mapk inhibitor/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
p38 mapk inhibitor - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
anti rabbit s100a16  (Proteintech)
93
Proteintech anti rabbit s100a16
Figure 1. <t>S100A16</t> is decreased in human colorectal cancer. (A)Analysis of S100A16 expression in normal colorectal tissues and colorectal adenocarcinoma tissues in the Skrzypczak in Oncomine microarray dataset, as assessed using an unpaired-t test. P<0.05. (B) Representative images of S100A16 protein expres sion in CRC tumour tissues and paired normal adjacent tissues, as assessed via immunohistochemistry. Magnification, x400. **P<0.01, paired Student's t-test. (C) Representative images of difference scores indicating S100A16 protein expression in CRC tumour tissues and paired normal adjacent tissues (magnifica tion, x400). The proportion of S100A16-expressing in CRC tissue samples was also analysed. **P<0.01, χ2 test. S100A16 (D) mRNA and (E) protein expression in CRC cell lines, as determined via reverse transcription-quantitative PCR and western blotting, respectively. (F) Kaplan-Meier analysis of the survival rates in patients with CRC with S100A16 low or high expression. CRC, colorectal cancer; S100A16, S100 calcium binding protein A16, IRS, immunoreactive score.
Anti Rabbit S100a16, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti rabbit s100a16/product/Proteintech
Average 93 stars, based on 1 article reviews
anti rabbit s100a16 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
tissue microarray data  (Human Protein Atlas)
90
Human Protein Atlas tissue microarray data
Figure 1. <t>S100A16</t> is decreased in human colorectal cancer. (A)Analysis of S100A16 expression in normal colorectal tissues and colorectal adenocarcinoma tissues in the Skrzypczak in Oncomine microarray dataset, as assessed using an unpaired-t test. P<0.05. (B) Representative images of S100A16 protein expres sion in CRC tumour tissues and paired normal adjacent tissues, as assessed via immunohistochemistry. Magnification, x400. **P<0.01, paired Student's t-test. (C) Representative images of difference scores indicating S100A16 protein expression in CRC tumour tissues and paired normal adjacent tissues (magnifica tion, x400). The proportion of S100A16-expressing in CRC tissue samples was also analysed. **P<0.01, χ2 test. S100A16 (D) mRNA and (E) protein expression in CRC cell lines, as determined via reverse transcription-quantitative PCR and western blotting, respectively. (F) Kaplan-Meier analysis of the survival rates in patients with CRC with S100A16 low or high expression. CRC, colorectal cancer; S100A16, S100 calcium binding protein A16, IRS, immunoreactive score.
Tissue Microarray Data, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tissue microarray data/product/Human Protein Atlas
Average 90 stars, based on 1 article reviews
tissue microarray data - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
g actin f actin in vivo assay biochem kit cytoskelton cat  (Dojindo Labs)
99
Dojindo Labs g actin f actin in vivo assay biochem kit cytoskelton cat
Figure 1. <t>S100A16</t> is decreased in human colorectal cancer. (A)Analysis of S100A16 expression in normal colorectal tissues and colorectal adenocarcinoma tissues in the Skrzypczak in Oncomine microarray dataset, as assessed using an unpaired-t test. P<0.05. (B) Representative images of S100A16 protein expres sion in CRC tumour tissues and paired normal adjacent tissues, as assessed via immunohistochemistry. Magnification, x400. **P<0.01, paired Student's t-test. (C) Representative images of difference scores indicating S100A16 protein expression in CRC tumour tissues and paired normal adjacent tissues (magnifica tion, x400). The proportion of S100A16-expressing in CRC tissue samples was also analysed. **P<0.01, χ2 test. S100A16 (D) mRNA and (E) protein expression in CRC cell lines, as determined via reverse transcription-quantitative PCR and western blotting, respectively. (F) Kaplan-Meier analysis of the survival rates in patients with CRC with S100A16 low or high expression. CRC, colorectal cancer; S100A16, S100 calcium binding protein A16, IRS, immunoreactive score.
G Actin F Actin In Vivo Assay Biochem Kit Cytoskelton Cat, supplied by Dojindo Labs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/g actin f actin in vivo assay biochem kit cytoskelton cat/product/Dojindo Labs
Average 99 stars, based on 1 article reviews
g actin f actin in vivo assay biochem kit cytoskelton cat - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
protein microarray kit  (Arrayit Corporation)
90
Arrayit Corporation protein microarray kit
Figure 1. <t>S100A16</t> is decreased in human colorectal cancer. (A)Analysis of S100A16 expression in normal colorectal tissues and colorectal adenocarcinoma tissues in the Skrzypczak in Oncomine microarray dataset, as assessed using an unpaired-t test. P<0.05. (B) Representative images of S100A16 protein expres sion in CRC tumour tissues and paired normal adjacent tissues, as assessed via immunohistochemistry. Magnification, x400. **P<0.01, paired Student's t-test. (C) Representative images of difference scores indicating S100A16 protein expression in CRC tumour tissues and paired normal adjacent tissues (magnifica tion, x400). The proportion of S100A16-expressing in CRC tissue samples was also analysed. **P<0.01, χ2 test. S100A16 (D) mRNA and (E) protein expression in CRC cell lines, as determined via reverse transcription-quantitative PCR and western blotting, respectively. (F) Kaplan-Meier analysis of the survival rates in patients with CRC with S100A16 low or high expression. CRC, colorectal cancer; S100A16, S100 calcium binding protein A16, IRS, immunoreactive score.
Protein Microarray Kit, supplied by Arrayit Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/protein microarray kit/product/Arrayit Corporation
Average 90 stars, based on 1 article reviews
protein microarray kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sp 2001 bca protein assay kit takara  (Vector Laboratories)
96
Vector Laboratories sp 2001 bca protein assay kit takara
Figure 1. <t>S100A16</t> is decreased in human colorectal cancer. (A)Analysis of S100A16 expression in normal colorectal tissues and colorectal adenocarcinoma tissues in the Skrzypczak in Oncomine microarray dataset, as assessed using an unpaired-t test. P<0.05. (B) Representative images of S100A16 protein expres sion in CRC tumour tissues and paired normal adjacent tissues, as assessed via immunohistochemistry. Magnification, x400. **P<0.01, paired Student's t-test. (C) Representative images of difference scores indicating S100A16 protein expression in CRC tumour tissues and paired normal adjacent tissues (magnifica tion, x400). The proportion of S100A16-expressing in CRC tissue samples was also analysed. **P<0.01, χ2 test. S100A16 (D) mRNA and (E) protein expression in CRC cell lines, as determined via reverse transcription-quantitative PCR and western blotting, respectively. (F) Kaplan-Meier analysis of the survival rates in patients with CRC with S100A16 low or high expression. CRC, colorectal cancer; S100A16, S100 calcium binding protein A16, IRS, immunoreactive score.
Sp 2001 Bca Protein Assay Kit Takara, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sp 2001 bca protein assay kit takara/product/Vector Laboratories
Average 96 stars, based on 1 article reviews
sp 2001 bca protein assay kit takara - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
mhy1485 selleckchem cat  (Selleck Chemicals)
94
Selleck Chemicals mhy1485 selleckchem cat
Figure 1. <t>S100A16</t> is decreased in human colorectal cancer. (A)Analysis of S100A16 expression in normal colorectal tissues and colorectal adenocarcinoma tissues in the Skrzypczak in Oncomine microarray dataset, as assessed using an unpaired-t test. P<0.05. (B) Representative images of S100A16 protein expres sion in CRC tumour tissues and paired normal adjacent tissues, as assessed via immunohistochemistry. Magnification, x400. **P<0.01, paired Student's t-test. (C) Representative images of difference scores indicating S100A16 protein expression in CRC tumour tissues and paired normal adjacent tissues (magnifica tion, x400). The proportion of S100A16-expressing in CRC tissue samples was also analysed. **P<0.01, χ2 test. S100A16 (D) mRNA and (E) protein expression in CRC cell lines, as determined via reverse transcription-quantitative PCR and western blotting, respectively. (F) Kaplan-Meier analysis of the survival rates in patients with CRC with S100A16 low or high expression. CRC, colorectal cancer; S100A16, S100 calcium binding protein A16, IRS, immunoreactive score.
Mhy1485 Selleckchem Cat, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mhy1485 selleckchem cat/product/Selleck Chemicals
Average 94 stars, based on 1 article reviews
mhy1485 selleckchem cat - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
traf7 antibodies  (Proteintech)
93
Proteintech traf7 antibodies
Figure 3 Validation of cba-miR-222-3p targeting <t>TRAF7</t> and TRAF7 expression in the testes of striped hamsters. (a) Sequences and peak maps of cba-miR-222-3p, TRAF7-WT, and TRAF7-MT. (b) Relative luciferase activity detected by Dual-Luciferase Reporter Assay. (c) Immunohistochemistry (IHC, tissue microarray [TMA]) of TRAF7 in testes. (d) Integrated density of TRAF7 detected by IHC (TMA; n = 4). (e) Protein expression levels of TRAF7 in the testes detected by western blot (n = 4). (f) Pearson correlation analysis of cba-miR-222-3p and TRAF7. LD, long daylength; MD, moderate daylength; SD, short daylength; ∗, P < 0.05; ∗∗, P < 0.01.
Traf7 Antibodies, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/traf7 antibodies/product/Proteintech
Average 93 stars, based on 1 article reviews
traf7 antibodies - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


Figure 4. Identification of Tinagl1-Interacting Proteins (A–C) LM2 cells expressing the C-terminal HA-tagged Tinagl1 (Tinagl1-HA) were lysed and immunoprecipitated (IP) with immunoglobulin G (IgG) (control) or anti- HA antibody. The IP samples were subjected to silver staining and WB (A) before mass spectrometry analysis. Tinagl1-interacting partners were clustered with KEGG pathway analysis, and the three top pathways are shown in (B). The members of the top three pathways have overlaps. The EGFR and integrin b1 subunits are the core members of each pathways (C). (D and E) LM2 cells stably expressing Tinagl1-HA were lysed and IP with IgG or anti-HA antibodies. The IP samples were subjected to WB analysis with the indicated antibodies to detect the interaction with EGFR and the integrin b1 subunit (D), and with integrins av, or a5 subunits (E). See also Figure S4.

Journal: Cancer cell

Article Title: Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling.

doi: 10.1016/j.ccell.2018.11.016

Figure Lengend Snippet: Figure 4. Identification of Tinagl1-Interacting Proteins (A–C) LM2 cells expressing the C-terminal HA-tagged Tinagl1 (Tinagl1-HA) were lysed and immunoprecipitated (IP) with immunoglobulin G (IgG) (control) or anti- HA antibody. The IP samples were subjected to silver staining and WB (A) before mass spectrometry analysis. Tinagl1-interacting partners were clustered with KEGG pathway analysis, and the three top pathways are shown in (B). The members of the top three pathways have overlaps. The EGFR and integrin b1 subunits are the core members of each pathways (C). (D and E) LM2 cells stably expressing Tinagl1-HA were lysed and IP with IgG or anti-HA antibodies. The IP samples were subjected to WB analysis with the indicated antibodies to detect the interaction with EGFR and the integrin b1 subunit (D), and with integrins av, or a5 subunits (E). See also Figure S4.

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Tinagl1, in 1:1000 (WB), 2 mg (IP), Rabbit ProteinTech Cat#12077-1-AP; RRID: AB_2058942 Tinagl1, in 1:100 (IHC), Rabbit Sigma-Aldrich Cat#HPA048695; RRID: AB_2680497 b-actin, in 1:10,000 (WB), mouse Abcam Cat#ab6276; RRID: AB_2223210 EGFR, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4267; RRID: AB_2246311 p-EGFR (Try1068), in 1:1000 (WB), 1:100 (IHC), Rabbit Cell Signaling Technology Cat#3777; RRID: AB_2096270 FAK, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#3285; RRID: AB_10694068 p-FAK (Try397), in 1:1000 (WB), 1:100 (IHC), Rabbit Cell Signaling Technology Cat#8556; RRID: AB_10891442 p-FAK (Try925), in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#3284; RRID: AB_2253227 AKT, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4691; RRID: AB_915783 p-ATK (S473), in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4060; RRID: AB_2315049 ERK1/2, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4695; RRID: AB_390779 p-ERK1/2 (Thr202/Tyr204), in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4370; RRID: AB_2315112 Integrin b1 subunit, in 1:1000 (WB), 2 mg (IP), Rabbit Cell Signaling Technology Cat#34971 Integrin a5 subunit, in 1:1000 (WB), 2 mg (IP), Rabbit Cell Signaling Technology Cat#4705; RRID: AB_10827978 Integrin av subunit, in 1:1000 (WB), 2 mg (IP), Rabbit Abcam Cat#ab179475; RRID: AB_2716738 Integrin a3 subunit, in 1:1000 (WB), Rabbit Abcam Cat#ab190731 Integrin a4 subunit, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#8440P Integrin aM subunit, in 1:1000 (WB), Rabbit Abcam Cat#ab8878; RRID: AB_306831 HA, in 2 mg (IP), Mouse Santa Cruz Biotechnology Cat#sc-7392; RRID: AB_627809 HA, in 1:1000 (WB), Rat Roche, 11867423001 Cat#11867423001; RRID: AB_10094468 MYC, in 1:1000 (WB), 2 mg (IP), Mouse Santa Cruz Biotechnology Cat#sc-40; RRID: AB_627268 FLAG, in 1:1000 (WB), 2 mg (IP), Mouse Sigma-Aldrich Cat#F7425; RRID: AB_439687 His, in 1:1000 (WB), Mouse Sigma-Aldrich Cat#H1029; RRID: AB_260015 GFP, in 1:1000 (WB), Mouse Santa Cruz Biotechnology Cat#sc-9996; RRID: AB_627695 Fibronectin, in 1:1000 (WB), Rabbit ProteinTech Cat#15613-1-AP; RRID: AB_2105691 EGF, in 1:1000 (WB), Mouse Santa Cruz Biotechnology Cat#sc-275; RRID: AB_631417 (Continued on next page) e1 Cancer Cell 35, 1–17.e1–e7, January 14, 2019

Techniques: Expressing, Immunoprecipitation, Control, Silver Staining, Mass Spectrometry, Stable Transfection

Figure 5. Tinagl1 Inhibits integrin/FAK and EGFR Signaling Pathways (A) Gene set enrichment analysis of lung metastatic nodules formed by LM2 cells stably expressing the vector control or Tinagl1 were dissected and digested. n = 3 per group. (B) Heatmap representation of microarray data displaying the expression of EGFR or integrin/FAK regulated genes in the control versus Tinagl1-expressing LM2 cells. (C) Heatmap representation of microarray data displaying the expression of genes compensated by integrin/FAK (left) or EGFR (right) in control versus Tinagl1- expressing LM2 cells.

Journal: Cancer cell

Article Title: Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling.

doi: 10.1016/j.ccell.2018.11.016

Figure Lengend Snippet: Figure 5. Tinagl1 Inhibits integrin/FAK and EGFR Signaling Pathways (A) Gene set enrichment analysis of lung metastatic nodules formed by LM2 cells stably expressing the vector control or Tinagl1 were dissected and digested. n = 3 per group. (B) Heatmap representation of microarray data displaying the expression of EGFR or integrin/FAK regulated genes in the control versus Tinagl1-expressing LM2 cells. (C) Heatmap representation of microarray data displaying the expression of genes compensated by integrin/FAK (left) or EGFR (right) in control versus Tinagl1- expressing LM2 cells.

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Tinagl1, in 1:1000 (WB), 2 mg (IP), Rabbit ProteinTech Cat#12077-1-AP; RRID: AB_2058942 Tinagl1, in 1:100 (IHC), Rabbit Sigma-Aldrich Cat#HPA048695; RRID: AB_2680497 b-actin, in 1:10,000 (WB), mouse Abcam Cat#ab6276; RRID: AB_2223210 EGFR, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4267; RRID: AB_2246311 p-EGFR (Try1068), in 1:1000 (WB), 1:100 (IHC), Rabbit Cell Signaling Technology Cat#3777; RRID: AB_2096270 FAK, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#3285; RRID: AB_10694068 p-FAK (Try397), in 1:1000 (WB), 1:100 (IHC), Rabbit Cell Signaling Technology Cat#8556; RRID: AB_10891442 p-FAK (Try925), in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#3284; RRID: AB_2253227 AKT, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4691; RRID: AB_915783 p-ATK (S473), in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4060; RRID: AB_2315049 ERK1/2, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4695; RRID: AB_390779 p-ERK1/2 (Thr202/Tyr204), in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4370; RRID: AB_2315112 Integrin b1 subunit, in 1:1000 (WB), 2 mg (IP), Rabbit Cell Signaling Technology Cat#34971 Integrin a5 subunit, in 1:1000 (WB), 2 mg (IP), Rabbit Cell Signaling Technology Cat#4705; RRID: AB_10827978 Integrin av subunit, in 1:1000 (WB), 2 mg (IP), Rabbit Abcam Cat#ab179475; RRID: AB_2716738 Integrin a3 subunit, in 1:1000 (WB), Rabbit Abcam Cat#ab190731 Integrin a4 subunit, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#8440P Integrin aM subunit, in 1:1000 (WB), Rabbit Abcam Cat#ab8878; RRID: AB_306831 HA, in 2 mg (IP), Mouse Santa Cruz Biotechnology Cat#sc-7392; RRID: AB_627809 HA, in 1:1000 (WB), Rat Roche, 11867423001 Cat#11867423001; RRID: AB_10094468 MYC, in 1:1000 (WB), 2 mg (IP), Mouse Santa Cruz Biotechnology Cat#sc-40; RRID: AB_627268 FLAG, in 1:1000 (WB), 2 mg (IP), Mouse Sigma-Aldrich Cat#F7425; RRID: AB_439687 His, in 1:1000 (WB), Mouse Sigma-Aldrich Cat#H1029; RRID: AB_260015 GFP, in 1:1000 (WB), Mouse Santa Cruz Biotechnology Cat#sc-9996; RRID: AB_627695 Fibronectin, in 1:1000 (WB), Rabbit ProteinTech Cat#15613-1-AP; RRID: AB_2105691 EGF, in 1:1000 (WB), Mouse Santa Cruz Biotechnology Cat#sc-275; RRID: AB_631417 (Continued on next page) e1 Cancer Cell 35, 1–17.e1–e7, January 14, 2019

Techniques: Protein-Protein interactions, Stable Transfection, Expressing, Plasmid Preparation, Control, Microarray

Figure 6. Tinagl1 Inhibits EGFR Dimerization and Blocks the Interaction between the Integrin b1 Subunit and FN (A) LM2 cells were transfected with plasmids to overexpress GFP-EGFR and EGFR-Myc. 48 hr after transfection, the cells were treated with or without 1 mg/mL of r-Tinagl1 for 1 hr, followed by 10 min of 1 ng/mL EGF treatment. The cells were then collected and immunoprecipitated with either IgG or anti-Myc antibody. IP samples were subjected to WB analysis (top), and the amount of EGFR-GFP that interacts with EGFR-Myc was quantified and normalized to the PBS treatment group (bottom). (B) LM2 cells stably expressing EGFR-Myc were pre-treated with PBS or 1 mg/mL of r-Tinagl1 for 1 hr and then treated with 1 ng/mL of EGF for another 10 min. Next, the cells were collected and the dimers were crosslinked with disuccinimidyl suberate (DSS) treatment, followed by WB analysis (top) and quantification of the ratio of dimerized EGFR in each treatment group (bottom). (C) HEK293T cells overexpressing the integrin b1 subunit were lysed. 20 mg of FN was added into the lysate, and the lysate was divided into eight groups. PBS or the indicated amount of proteins were added into each group followed by IP with IgG or anti-b1 antibody. The IP samples were then subjected to WB analysis. (D) HEK293T cells overexpressing both integrin b1 subunit and Tinagl1-HA were lysed and divided into eight groups. PBS or the indicated amount of proteins were added into the lysate, followed by IP and WB analysis.

Journal: Cancer cell

Article Title: Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling.

doi: 10.1016/j.ccell.2018.11.016

Figure Lengend Snippet: Figure 6. Tinagl1 Inhibits EGFR Dimerization and Blocks the Interaction between the Integrin b1 Subunit and FN (A) LM2 cells were transfected with plasmids to overexpress GFP-EGFR and EGFR-Myc. 48 hr after transfection, the cells were treated with or without 1 mg/mL of r-Tinagl1 for 1 hr, followed by 10 min of 1 ng/mL EGF treatment. The cells were then collected and immunoprecipitated with either IgG or anti-Myc antibody. IP samples were subjected to WB analysis (top), and the amount of EGFR-GFP that interacts with EGFR-Myc was quantified and normalized to the PBS treatment group (bottom). (B) LM2 cells stably expressing EGFR-Myc were pre-treated with PBS or 1 mg/mL of r-Tinagl1 for 1 hr and then treated with 1 ng/mL of EGF for another 10 min. Next, the cells were collected and the dimers were crosslinked with disuccinimidyl suberate (DSS) treatment, followed by WB analysis (top) and quantification of the ratio of dimerized EGFR in each treatment group (bottom). (C) HEK293T cells overexpressing the integrin b1 subunit were lysed. 20 mg of FN was added into the lysate, and the lysate was divided into eight groups. PBS or the indicated amount of proteins were added into each group followed by IP with IgG or anti-b1 antibody. The IP samples were then subjected to WB analysis. (D) HEK293T cells overexpressing both integrin b1 subunit and Tinagl1-HA were lysed and divided into eight groups. PBS or the indicated amount of proteins were added into the lysate, followed by IP and WB analysis.

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Tinagl1, in 1:1000 (WB), 2 mg (IP), Rabbit ProteinTech Cat#12077-1-AP; RRID: AB_2058942 Tinagl1, in 1:100 (IHC), Rabbit Sigma-Aldrich Cat#HPA048695; RRID: AB_2680497 b-actin, in 1:10,000 (WB), mouse Abcam Cat#ab6276; RRID: AB_2223210 EGFR, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4267; RRID: AB_2246311 p-EGFR (Try1068), in 1:1000 (WB), 1:100 (IHC), Rabbit Cell Signaling Technology Cat#3777; RRID: AB_2096270 FAK, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#3285; RRID: AB_10694068 p-FAK (Try397), in 1:1000 (WB), 1:100 (IHC), Rabbit Cell Signaling Technology Cat#8556; RRID: AB_10891442 p-FAK (Try925), in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#3284; RRID: AB_2253227 AKT, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4691; RRID: AB_915783 p-ATK (S473), in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4060; RRID: AB_2315049 ERK1/2, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4695; RRID: AB_390779 p-ERK1/2 (Thr202/Tyr204), in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4370; RRID: AB_2315112 Integrin b1 subunit, in 1:1000 (WB), 2 mg (IP), Rabbit Cell Signaling Technology Cat#34971 Integrin a5 subunit, in 1:1000 (WB), 2 mg (IP), Rabbit Cell Signaling Technology Cat#4705; RRID: AB_10827978 Integrin av subunit, in 1:1000 (WB), 2 mg (IP), Rabbit Abcam Cat#ab179475; RRID: AB_2716738 Integrin a3 subunit, in 1:1000 (WB), Rabbit Abcam Cat#ab190731 Integrin a4 subunit, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#8440P Integrin aM subunit, in 1:1000 (WB), Rabbit Abcam Cat#ab8878; RRID: AB_306831 HA, in 2 mg (IP), Mouse Santa Cruz Biotechnology Cat#sc-7392; RRID: AB_627809 HA, in 1:1000 (WB), Rat Roche, 11867423001 Cat#11867423001; RRID: AB_10094468 MYC, in 1:1000 (WB), 2 mg (IP), Mouse Santa Cruz Biotechnology Cat#sc-40; RRID: AB_627268 FLAG, in 1:1000 (WB), 2 mg (IP), Mouse Sigma-Aldrich Cat#F7425; RRID: AB_439687 His, in 1:1000 (WB), Mouse Sigma-Aldrich Cat#H1029; RRID: AB_260015 GFP, in 1:1000 (WB), Mouse Santa Cruz Biotechnology Cat#sc-9996; RRID: AB_627695 Fibronectin, in 1:1000 (WB), Rabbit ProteinTech Cat#15613-1-AP; RRID: AB_2105691 EGF, in 1:1000 (WB), Mouse Santa Cruz Biotechnology Cat#sc-275; RRID: AB_631417 (Continued on next page) e1 Cancer Cell 35, 1–17.e1–e7, January 14, 2019

Techniques: Transfection, Immunoprecipitation, Stable Transfection, Expressing

Figure 7. Tinagl1 Inhibits TNBC Progression by Simultaneously Targeting the Integrin/FAK and EGFR Signaling Pathways (A) 104 LM2 cells was injected into the MFP of NSG mice. Mice were intravenously treated with the indicated reagents twice per week when tumors reached 2 mm in diameter. n = 6 mice per group. (B) WB analysis for the activation of EGFR and FAK in primary tumor of each group after 5 weeks of the treatments as in (A). (C) Quantification of tumor volumes of each treatment group of (A). n = 12 tumors per group. (D and E) Lungs were collected and spontaneous metastasis was examined by ex vivo BLI at the endpoint. n = 6 lungs per group. Representative lungs (D) and quantitative data (E) is shown. Data represent means ± SEM. n.s., not significant; p > 0.05, **p < 0.001, ***p < 0.0001. Significance determined by one-way ANOVA analysis with Dunnett’s test for multiple comparisons. See also Figure S7.

Journal: Cancer cell

Article Title: Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling.

doi: 10.1016/j.ccell.2018.11.016

Figure Lengend Snippet: Figure 7. Tinagl1 Inhibits TNBC Progression by Simultaneously Targeting the Integrin/FAK and EGFR Signaling Pathways (A) 104 LM2 cells was injected into the MFP of NSG mice. Mice were intravenously treated with the indicated reagents twice per week when tumors reached 2 mm in diameter. n = 6 mice per group. (B) WB analysis for the activation of EGFR and FAK in primary tumor of each group after 5 weeks of the treatments as in (A). (C) Quantification of tumor volumes of each treatment group of (A). n = 12 tumors per group. (D and E) Lungs were collected and spontaneous metastasis was examined by ex vivo BLI at the endpoint. n = 6 lungs per group. Representative lungs (D) and quantitative data (E) is shown. Data represent means ± SEM. n.s., not significant; p > 0.05, **p < 0.001, ***p < 0.0001. Significance determined by one-way ANOVA analysis with Dunnett’s test for multiple comparisons. See also Figure S7.

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Tinagl1, in 1:1000 (WB), 2 mg (IP), Rabbit ProteinTech Cat#12077-1-AP; RRID: AB_2058942 Tinagl1, in 1:100 (IHC), Rabbit Sigma-Aldrich Cat#HPA048695; RRID: AB_2680497 b-actin, in 1:10,000 (WB), mouse Abcam Cat#ab6276; RRID: AB_2223210 EGFR, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4267; RRID: AB_2246311 p-EGFR (Try1068), in 1:1000 (WB), 1:100 (IHC), Rabbit Cell Signaling Technology Cat#3777; RRID: AB_2096270 FAK, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#3285; RRID: AB_10694068 p-FAK (Try397), in 1:1000 (WB), 1:100 (IHC), Rabbit Cell Signaling Technology Cat#8556; RRID: AB_10891442 p-FAK (Try925), in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#3284; RRID: AB_2253227 AKT, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4691; RRID: AB_915783 p-ATK (S473), in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4060; RRID: AB_2315049 ERK1/2, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4695; RRID: AB_390779 p-ERK1/2 (Thr202/Tyr204), in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#4370; RRID: AB_2315112 Integrin b1 subunit, in 1:1000 (WB), 2 mg (IP), Rabbit Cell Signaling Technology Cat#34971 Integrin a5 subunit, in 1:1000 (WB), 2 mg (IP), Rabbit Cell Signaling Technology Cat#4705; RRID: AB_10827978 Integrin av subunit, in 1:1000 (WB), 2 mg (IP), Rabbit Abcam Cat#ab179475; RRID: AB_2716738 Integrin a3 subunit, in 1:1000 (WB), Rabbit Abcam Cat#ab190731 Integrin a4 subunit, in 1:1000 (WB), Rabbit Cell Signaling Technology Cat#8440P Integrin aM subunit, in 1:1000 (WB), Rabbit Abcam Cat#ab8878; RRID: AB_306831 HA, in 2 mg (IP), Mouse Santa Cruz Biotechnology Cat#sc-7392; RRID: AB_627809 HA, in 1:1000 (WB), Rat Roche, 11867423001 Cat#11867423001; RRID: AB_10094468 MYC, in 1:1000 (WB), 2 mg (IP), Mouse Santa Cruz Biotechnology Cat#sc-40; RRID: AB_627268 FLAG, in 1:1000 (WB), 2 mg (IP), Mouse Sigma-Aldrich Cat#F7425; RRID: AB_439687 His, in 1:1000 (WB), Mouse Sigma-Aldrich Cat#H1029; RRID: AB_260015 GFP, in 1:1000 (WB), Mouse Santa Cruz Biotechnology Cat#sc-9996; RRID: AB_627695 Fibronectin, in 1:1000 (WB), Rabbit ProteinTech Cat#15613-1-AP; RRID: AB_2105691 EGF, in 1:1000 (WB), Mouse Santa Cruz Biotechnology Cat#sc-275; RRID: AB_631417 (Continued on next page) e1 Cancer Cell 35, 1–17.e1–e7, January 14, 2019

Techniques: Protein-Protein interactions, Injection, Activation Assay, Ex Vivo

Figure 1. S100A16 is decreased in human colorectal cancer. (A)Analysis of S100A16 expression in normal colorectal tissues and colorectal adenocarcinoma tissues in the Skrzypczak in Oncomine microarray dataset, as assessed using an unpaired-t test. P<0.05. (B) Representative images of S100A16 protein expres sion in CRC tumour tissues and paired normal adjacent tissues, as assessed via immunohistochemistry. Magnification, x400. **P<0.01, paired Student's t-test. (C) Representative images of difference scores indicating S100A16 protein expression in CRC tumour tissues and paired normal adjacent tissues (magnifica tion, x400). The proportion of S100A16-expressing in CRC tissue samples was also analysed. **P<0.01, χ2 test. S100A16 (D) mRNA and (E) protein expression in CRC cell lines, as determined via reverse transcription-quantitative PCR and western blotting, respectively. (F) Kaplan-Meier analysis of the survival rates in patients with CRC with S100A16 low or high expression. CRC, colorectal cancer; S100A16, S100 calcium binding protein A16, IRS, immunoreactive score.

Journal: Molecular medicine reports

Article Title: S100A16 suppresses the proliferation, migration and invasion of colorectal cancer cells in part via the JNK/p38 MAPK pathway.

doi: 10.3892/mmr.2020.11803

Figure Lengend Snippet: Figure 1. S100A16 is decreased in human colorectal cancer. (A)Analysis of S100A16 expression in normal colorectal tissues and colorectal adenocarcinoma tissues in the Skrzypczak in Oncomine microarray dataset, as assessed using an unpaired-t test. P<0.05. (B) Representative images of S100A16 protein expres sion in CRC tumour tissues and paired normal adjacent tissues, as assessed via immunohistochemistry. Magnification, x400. **P<0.01, paired Student's t-test. (C) Representative images of difference scores indicating S100A16 protein expression in CRC tumour tissues and paired normal adjacent tissues (magnifica tion, x400). The proportion of S100A16-expressing in CRC tissue samples was also analysed. **P<0.01, χ2 test. S100A16 (D) mRNA and (E) protein expression in CRC cell lines, as determined via reverse transcription-quantitative PCR and western blotting, respectively. (F) Kaplan-Meier analysis of the survival rates in patients with CRC with S100A16 low or high expression. CRC, colorectal cancer; S100A16, S100 calcium binding protein A16, IRS, immunoreactive score.

Article Snippet: After being blocked with non-fat milk for 1 h at room temperature, the membranes were incubated with the following primary antibodies at 4 ̊C overnight: anti-rabbit S100A4 (cat. no. 16105-1-AP; 1:500; ProteinTech Group, Inc.), anti-rabbit S100A14 (cat. no. 10489-1-AP; 1:500; ProteinTech Group, Inc.), anti-rabbit S100A16 (cat. no. 11456-1-AP; 1:500; ProteinTech Group, Inc.) anti-phosphorylated (p)-rabbit JNK (cat. no. 9255; Cell Signaling Technology, Inc.), anti-rabbit JNK (cat. no. 9252; Cell Signaling Technology, Inc.), anti-prabbit ERK1/2 (cat. no. 4370; Cell Signaling Technology, Inc.), anti-rabbit ERK1/2 (cat. no. 4695; Cell Signaling Technology, Inc.), anti-p-rabbit p38 MAPK (cat. no. 9216; Cell Signaling Technology, Inc.), anti-rabbit p38 MAPK (cat. no. 9212; Cell Signaling Technology, Inc.), anti-rabbit vimentin (cat. no. 12826; Cell Signaling Technology, Inc.), anti-mouse E-cadherin (cat. no. 14472; Cell Signaling Technology, Inc.), anti-mouse N-cadherin (cat. no. 14215; Cell Signaling Technology, Inc.) and anti-mouse GAPDH (cat. no. 51332; Cell Signaling Technology, Inc.).

Techniques: Expressing, Microarray, Immunohistochemistry, Reverse Transcription, Real-time Polymerase Chain Reaction, Western Blot, Binding Assay

Figure 2. S100A16 inhibits the proliferation of CRC cells. (A) Western blot analysis of S100A16 protein expression in CRC cells transfected with S100A16 siRNAs compared with si-Ctrl. Data were analysed using a one-way ANOVA followed by Tukey's post hoc test. **P<0.01. (B) Western blot analysis of S100A16 protein expression in CRC cells transfected with overexpression plasmids compared vectors, as assessed using an unpaired Student's t-test. **P<0.01. (C) S100A16 knockdown promoted the proliferation of HCT116 and SW480 cells. *P<0.05, vs. si-Ctrl. (D) S100A16 overexpression suppressed the proliferation of Lovo cells. *P<0.05. Cell proliferation was examined by performing Cell Counting Kit-8 assays and analysed using a two-way ANOVA with Bonferronis correction. CRC, colorectal cancer; siRNA/si, small interfering RNA; Ctrl, control; S100A16, S100 calcium binding protein A16; OD, optical density.

Journal: Molecular medicine reports

Article Title: S100A16 suppresses the proliferation, migration and invasion of colorectal cancer cells in part via the JNK/p38 MAPK pathway.

doi: 10.3892/mmr.2020.11803

Figure Lengend Snippet: Figure 2. S100A16 inhibits the proliferation of CRC cells. (A) Western blot analysis of S100A16 protein expression in CRC cells transfected with S100A16 siRNAs compared with si-Ctrl. Data were analysed using a one-way ANOVA followed by Tukey's post hoc test. **P<0.01. (B) Western blot analysis of S100A16 protein expression in CRC cells transfected with overexpression plasmids compared vectors, as assessed using an unpaired Student's t-test. **P<0.01. (C) S100A16 knockdown promoted the proliferation of HCT116 and SW480 cells. *P<0.05, vs. si-Ctrl. (D) S100A16 overexpression suppressed the proliferation of Lovo cells. *P<0.05. Cell proliferation was examined by performing Cell Counting Kit-8 assays and analysed using a two-way ANOVA with Bonferronis correction. CRC, colorectal cancer; siRNA/si, small interfering RNA; Ctrl, control; S100A16, S100 calcium binding protein A16; OD, optical density.

Article Snippet: After being blocked with non-fat milk for 1 h at room temperature, the membranes were incubated with the following primary antibodies at 4 ̊C overnight: anti-rabbit S100A4 (cat. no. 16105-1-AP; 1:500; ProteinTech Group, Inc.), anti-rabbit S100A14 (cat. no. 10489-1-AP; 1:500; ProteinTech Group, Inc.), anti-rabbit S100A16 (cat. no. 11456-1-AP; 1:500; ProteinTech Group, Inc.) anti-phosphorylated (p)-rabbit JNK (cat. no. 9255; Cell Signaling Technology, Inc.), anti-rabbit JNK (cat. no. 9252; Cell Signaling Technology, Inc.), anti-prabbit ERK1/2 (cat. no. 4370; Cell Signaling Technology, Inc.), anti-rabbit ERK1/2 (cat. no. 4695; Cell Signaling Technology, Inc.), anti-p-rabbit p38 MAPK (cat. no. 9216; Cell Signaling Technology, Inc.), anti-rabbit p38 MAPK (cat. no. 9212; Cell Signaling Technology, Inc.), anti-rabbit vimentin (cat. no. 12826; Cell Signaling Technology, Inc.), anti-mouse E-cadherin (cat. no. 14472; Cell Signaling Technology, Inc.), anti-mouse N-cadherin (cat. no. 14215; Cell Signaling Technology, Inc.) and anti-mouse GAPDH (cat. no. 51332; Cell Signaling Technology, Inc.).

Techniques: Western Blot, Expressing, Transfection, Over Expression, Knockdown, Cell Counting, Small Interfering RNA, Control, Binding Assay

Figure 4. S100A16 knockdown activates the JNK/p38 MAPK signalling pathway and promotes EMT. MAPK pathway-associated and EMT-associated pro teins were assessed via western blotting in HCT116 cells. Data were analysed with a one-way ANOVA followed by Tukey's post hoc test. **P<0.01; #P>0.05 (not significant). EMT, epithelial-mesenchymal transition; S100A16, S100 calcium binding protein A16; p-, phosphorylated; E-cad, E-cadherin; siRNA/si, small interfering RNA; Ctrl, control; N-cad, N-cadherin.

Journal: Molecular medicine reports

Article Title: S100A16 suppresses the proliferation, migration and invasion of colorectal cancer cells in part via the JNK/p38 MAPK pathway.

doi: 10.3892/mmr.2020.11803

Figure Lengend Snippet: Figure 4. S100A16 knockdown activates the JNK/p38 MAPK signalling pathway and promotes EMT. MAPK pathway-associated and EMT-associated pro teins were assessed via western blotting in HCT116 cells. Data were analysed with a one-way ANOVA followed by Tukey's post hoc test. **P<0.01; #P>0.05 (not significant). EMT, epithelial-mesenchymal transition; S100A16, S100 calcium binding protein A16; p-, phosphorylated; E-cad, E-cadherin; siRNA/si, small interfering RNA; Ctrl, control; N-cad, N-cadherin.

Article Snippet: After being blocked with non-fat milk for 1 h at room temperature, the membranes were incubated with the following primary antibodies at 4 ̊C overnight: anti-rabbit S100A4 (cat. no. 16105-1-AP; 1:500; ProteinTech Group, Inc.), anti-rabbit S100A14 (cat. no. 10489-1-AP; 1:500; ProteinTech Group, Inc.), anti-rabbit S100A16 (cat. no. 11456-1-AP; 1:500; ProteinTech Group, Inc.) anti-phosphorylated (p)-rabbit JNK (cat. no. 9255; Cell Signaling Technology, Inc.), anti-rabbit JNK (cat. no. 9252; Cell Signaling Technology, Inc.), anti-prabbit ERK1/2 (cat. no. 4370; Cell Signaling Technology, Inc.), anti-rabbit ERK1/2 (cat. no. 4695; Cell Signaling Technology, Inc.), anti-p-rabbit p38 MAPK (cat. no. 9216; Cell Signaling Technology, Inc.), anti-rabbit p38 MAPK (cat. no. 9212; Cell Signaling Technology, Inc.), anti-rabbit vimentin (cat. no. 12826; Cell Signaling Technology, Inc.), anti-mouse E-cadherin (cat. no. 14472; Cell Signaling Technology, Inc.), anti-mouse N-cadherin (cat. no. 14215; Cell Signaling Technology, Inc.) and anti-mouse GAPDH (cat. no. 51332; Cell Signaling Technology, Inc.).

Techniques: Knockdown, Western Blot, Binding Assay, Small Interfering RNA, Control

Figure 3. S100A16 inhibits CRC cell migration and invasion. (A) S100A16 knockdown promoted the migration and invasion of the two CRC cell lines, which was analysed using a one-way ANOVA followed by Tukey's post hoc test. **P<0.01. (B) S100A16 overexpression suppressed the migration and invasion of Lovo cells, which was analysed using an unpaired Student's t-test. **P<0.01. Cell migration and invasion were determined by performing Transwell assays. CRC, colorectal cancer; S100A16, S100 calcium binding protein A16; siRNA/si, small interfering RNA; Ctrl, control.

Journal: Molecular medicine reports

Article Title: S100A16 suppresses the proliferation, migration and invasion of colorectal cancer cells in part via the JNK/p38 MAPK pathway.

doi: 10.3892/mmr.2020.11803

Figure Lengend Snippet: Figure 3. S100A16 inhibits CRC cell migration and invasion. (A) S100A16 knockdown promoted the migration and invasion of the two CRC cell lines, which was analysed using a one-way ANOVA followed by Tukey's post hoc test. **P<0.01. (B) S100A16 overexpression suppressed the migration and invasion of Lovo cells, which was analysed using an unpaired Student's t-test. **P<0.01. Cell migration and invasion were determined by performing Transwell assays. CRC, colorectal cancer; S100A16, S100 calcium binding protein A16; siRNA/si, small interfering RNA; Ctrl, control.

Article Snippet: After being blocked with non-fat milk for 1 h at room temperature, the membranes were incubated with the following primary antibodies at 4 ̊C overnight: anti-rabbit S100A4 (cat. no. 16105-1-AP; 1:500; ProteinTech Group, Inc.), anti-rabbit S100A14 (cat. no. 10489-1-AP; 1:500; ProteinTech Group, Inc.), anti-rabbit S100A16 (cat. no. 11456-1-AP; 1:500; ProteinTech Group, Inc.) anti-phosphorylated (p)-rabbit JNK (cat. no. 9255; Cell Signaling Technology, Inc.), anti-rabbit JNK (cat. no. 9252; Cell Signaling Technology, Inc.), anti-prabbit ERK1/2 (cat. no. 4370; Cell Signaling Technology, Inc.), anti-rabbit ERK1/2 (cat. no. 4695; Cell Signaling Technology, Inc.), anti-p-rabbit p38 MAPK (cat. no. 9216; Cell Signaling Technology, Inc.), anti-rabbit p38 MAPK (cat. no. 9212; Cell Signaling Technology, Inc.), anti-rabbit vimentin (cat. no. 12826; Cell Signaling Technology, Inc.), anti-mouse E-cadherin (cat. no. 14472; Cell Signaling Technology, Inc.), anti-mouse N-cadherin (cat. no. 14215; Cell Signaling Technology, Inc.) and anti-mouse GAPDH (cat. no. 51332; Cell Signaling Technology, Inc.).

Techniques: Migration, Knockdown, Over Expression, Binding Assay, Small Interfering RNA, Control

Figure 5. JNK/p38 MAPK signalling pathway inactivation is required for S100A16 knockdown-mediated HCT116 cellular effects. (A) Representative images of Transwell assays after treatment with the p38 inhibitor (SB203580) or the JNK inhibitor (SP600125) following western blotting in S100A16-silenced HCT116 cells. (B) MAPK and epithelial-mesenchymal transition markers were examined via western blotting after treatment with the p38 inhibitor (SB203580) or the JNK inhibitor (SP600125) in S100A16-silenced HCT116 cells. Data were analysed with a one-way ANOVA followed by Tukey's post hoc test. **P<0.01 and *P<0.05; #P>0.05. S100A16, S100 calcium binding protein A16; p-, phosphorylated; E-cad, E-cadherin; siRNA/si, small interfering RNA; Ctrl, control; N-cad, N-cadherin.

Journal: Molecular medicine reports

Article Title: S100A16 suppresses the proliferation, migration and invasion of colorectal cancer cells in part via the JNK/p38 MAPK pathway.

doi: 10.3892/mmr.2020.11803

Figure Lengend Snippet: Figure 5. JNK/p38 MAPK signalling pathway inactivation is required for S100A16 knockdown-mediated HCT116 cellular effects. (A) Representative images of Transwell assays after treatment with the p38 inhibitor (SB203580) or the JNK inhibitor (SP600125) following western blotting in S100A16-silenced HCT116 cells. (B) MAPK and epithelial-mesenchymal transition markers were examined via western blotting after treatment with the p38 inhibitor (SB203580) or the JNK inhibitor (SP600125) in S100A16-silenced HCT116 cells. Data were analysed with a one-way ANOVA followed by Tukey's post hoc test. **P<0.01 and *P<0.05; #P>0.05. S100A16, S100 calcium binding protein A16; p-, phosphorylated; E-cad, E-cadherin; siRNA/si, small interfering RNA; Ctrl, control; N-cad, N-cadherin.

Article Snippet: After being blocked with non-fat milk for 1 h at room temperature, the membranes were incubated with the following primary antibodies at 4 ̊C overnight: anti-rabbit S100A4 (cat. no. 16105-1-AP; 1:500; ProteinTech Group, Inc.), anti-rabbit S100A14 (cat. no. 10489-1-AP; 1:500; ProteinTech Group, Inc.), anti-rabbit S100A16 (cat. no. 11456-1-AP; 1:500; ProteinTech Group, Inc.) anti-phosphorylated (p)-rabbit JNK (cat. no. 9255; Cell Signaling Technology, Inc.), anti-rabbit JNK (cat. no. 9252; Cell Signaling Technology, Inc.), anti-prabbit ERK1/2 (cat. no. 4370; Cell Signaling Technology, Inc.), anti-rabbit ERK1/2 (cat. no. 4695; Cell Signaling Technology, Inc.), anti-p-rabbit p38 MAPK (cat. no. 9216; Cell Signaling Technology, Inc.), anti-rabbit p38 MAPK (cat. no. 9212; Cell Signaling Technology, Inc.), anti-rabbit vimentin (cat. no. 12826; Cell Signaling Technology, Inc.), anti-mouse E-cadherin (cat. no. 14472; Cell Signaling Technology, Inc.), anti-mouse N-cadherin (cat. no. 14215; Cell Signaling Technology, Inc.) and anti-mouse GAPDH (cat. no. 51332; Cell Signaling Technology, Inc.).

Techniques: Knockdown, Western Blot, Binding Assay, Small Interfering RNA, Control

Figure 6. Overexpression of S100A16 inhibits tumour growth in vivo. (A) Images of tumour xenografts in mice of the vector and S100A16 groups. (B) Images of the isolated tumours. (C) Tumour volume and (D) weight were separately compared between the two groups. **P<0.01. S100A16, S100 calcium binding protein A16.

Journal: Molecular medicine reports

Article Title: S100A16 suppresses the proliferation, migration and invasion of colorectal cancer cells in part via the JNK/p38 MAPK pathway.

doi: 10.3892/mmr.2020.11803

Figure Lengend Snippet: Figure 6. Overexpression of S100A16 inhibits tumour growth in vivo. (A) Images of tumour xenografts in mice of the vector and S100A16 groups. (B) Images of the isolated tumours. (C) Tumour volume and (D) weight were separately compared between the two groups. **P<0.01. S100A16, S100 calcium binding protein A16.

Article Snippet: After being blocked with non-fat milk for 1 h at room temperature, the membranes were incubated with the following primary antibodies at 4 ̊C overnight: anti-rabbit S100A4 (cat. no. 16105-1-AP; 1:500; ProteinTech Group, Inc.), anti-rabbit S100A14 (cat. no. 10489-1-AP; 1:500; ProteinTech Group, Inc.), anti-rabbit S100A16 (cat. no. 11456-1-AP; 1:500; ProteinTech Group, Inc.) anti-phosphorylated (p)-rabbit JNK (cat. no. 9255; Cell Signaling Technology, Inc.), anti-rabbit JNK (cat. no. 9252; Cell Signaling Technology, Inc.), anti-prabbit ERK1/2 (cat. no. 4370; Cell Signaling Technology, Inc.), anti-rabbit ERK1/2 (cat. no. 4695; Cell Signaling Technology, Inc.), anti-p-rabbit p38 MAPK (cat. no. 9216; Cell Signaling Technology, Inc.), anti-rabbit p38 MAPK (cat. no. 9212; Cell Signaling Technology, Inc.), anti-rabbit vimentin (cat. no. 12826; Cell Signaling Technology, Inc.), anti-mouse E-cadherin (cat. no. 14472; Cell Signaling Technology, Inc.), anti-mouse N-cadherin (cat. no. 14215; Cell Signaling Technology, Inc.) and anti-mouse GAPDH (cat. no. 51332; Cell Signaling Technology, Inc.).

Techniques: Over Expression, In Vivo, Plasmid Preparation, Isolation, Binding Assay

Figure 3 Validation of cba-miR-222-3p targeting TRAF7 and TRAF7 expression in the testes of striped hamsters. (a) Sequences and peak maps of cba-miR-222-3p, TRAF7-WT, and TRAF7-MT. (b) Relative luciferase activity detected by Dual-Luciferase Reporter Assay. (c) Immunohistochemistry (IHC, tissue microarray [TMA]) of TRAF7 in testes. (d) Integrated density of TRAF7 detected by IHC (TMA; n = 4). (e) Protein expression levels of TRAF7 in the testes detected by western blot (n = 4). (f) Pearson correlation analysis of cba-miR-222-3p and TRAF7. LD, long daylength; MD, moderate daylength; SD, short daylength; ∗, P < 0.05; ∗∗, P < 0.01.

Journal: Integrative zoology

Article Title: cba-miR-222-3p involved in photoperiod-induced apoptosis in testes of striped hamsters by targeting TRAF7.

doi: 10.1111/1749-4877.12918

Figure Lengend Snippet: Figure 3 Validation of cba-miR-222-3p targeting TRAF7 and TRAF7 expression in the testes of striped hamsters. (a) Sequences and peak maps of cba-miR-222-3p, TRAF7-WT, and TRAF7-MT. (b) Relative luciferase activity detected by Dual-Luciferase Reporter Assay. (c) Immunohistochemistry (IHC, tissue microarray [TMA]) of TRAF7 in testes. (d) Integrated density of TRAF7 detected by IHC (TMA; n = 4). (e) Protein expression levels of TRAF7 in the testes detected by western blot (n = 4). (f) Pearson correlation analysis of cba-miR-222-3p and TRAF7. LD, long daylength; MD, moderate daylength; SD, short daylength; ∗, P < 0.05; ∗∗, P < 0.01.

Article Snippet: After performing electrophoresis, the proteins were transferred to PVDF membranes, which were then incubated with TRAF7 antibodies (11780-1-AP, Proteintech, China, RRID:AB_2877793) at a 1:1000 dilution and β-actin antibodies (20536-1-AP, Proteintech, China, RRID:AB_10700003) at a 1:1000 dilution, and subsequently incubated with IRDye 800 CW goat anti-rabbit secondary antibodies (31 460, Thermo Fisher, USA).

Techniques: Biomarker Discovery, Expressing, Luciferase, Activity Assay, Reporter Assay, Immunohistochemistry, Microarray, Western Blot

Figure 4 Expression of cba-miR-222-3p and TRAF7 and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analysis after in vivo injection in the testes of striped hamsters. (a) Schematic diagram of in vivo injection experiment of miRNA mimics. (b) Fluorescence in situ hybridization (FISH, tissue microarray [TMA]) of cba-miR-222-3p in testes after in vivo injection. (c) Fluorescence intensity of cba-miR-222-3p detected by FISH (TMA; n = 4). (d) Immunohistochemistry (IHC, TMA) of TRAF7 in testes after in vivo injection. (e) Integrated density of TRAF7 detected by IHC (TMA; n = 4). (f) TUNEL (TMA) staining of the testes after in vivo injection. (g) The proportion of TUNEL (TMA) staining with apoptotic activity in the testes (n = 4). (h) Relative expression of MEKK3 (n = 6). (i) Relative expression of p38 (n = 6). (j) Relative expression of p53 (n = 6). AG, agomir injection; NC, agomir negative control injection; DAPI, 4′6′-diamidino-2-phenylindole. ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗, P < 0.001.

Journal: Integrative zoology

Article Title: cba-miR-222-3p involved in photoperiod-induced apoptosis in testes of striped hamsters by targeting TRAF7.

doi: 10.1111/1749-4877.12918

Figure Lengend Snippet: Figure 4 Expression of cba-miR-222-3p and TRAF7 and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analysis after in vivo injection in the testes of striped hamsters. (a) Schematic diagram of in vivo injection experiment of miRNA mimics. (b) Fluorescence in situ hybridization (FISH, tissue microarray [TMA]) of cba-miR-222-3p in testes after in vivo injection. (c) Fluorescence intensity of cba-miR-222-3p detected by FISH (TMA; n = 4). (d) Immunohistochemistry (IHC, TMA) of TRAF7 in testes after in vivo injection. (e) Integrated density of TRAF7 detected by IHC (TMA; n = 4). (f) TUNEL (TMA) staining of the testes after in vivo injection. (g) The proportion of TUNEL (TMA) staining with apoptotic activity in the testes (n = 4). (h) Relative expression of MEKK3 (n = 6). (i) Relative expression of p38 (n = 6). (j) Relative expression of p53 (n = 6). AG, agomir injection; NC, agomir negative control injection; DAPI, 4′6′-diamidino-2-phenylindole. ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗, P < 0.001.

Article Snippet: After performing electrophoresis, the proteins were transferred to PVDF membranes, which were then incubated with TRAF7 antibodies (11780-1-AP, Proteintech, China, RRID:AB_2877793) at a 1:1000 dilution and β-actin antibodies (20536-1-AP, Proteintech, China, RRID:AB_10700003) at a 1:1000 dilution, and subsequently incubated with IRDye 800 CW goat anti-rabbit secondary antibodies (31 460, Thermo Fisher, USA).

Techniques: Expressing, TUNEL Assay, In Vivo, Injection, Fluorescence, In Situ Hybridization, Microarray, Immunohistochemistry, Staining, Activity Assay, Negative Control